Current barriers, challenges and opportunities for the development of effective STI vaccines: Point of view of vaccine producers, biotech companies and funding agencies

Vaccine

Volumn 32, Issue 14, 2014, Pages 1624-1629

  Dodet, Betty ^a  

^a Dodet Bioscience   (France)

Author keywords

Correlate of protection; STI burden; STI vaccine development; Vaccine companies

Indexed keywords

NEUTRALIZING ANTIBODY; SEXUALLY TRANSMITTED DISEASE VACCINE; UNCLASSIFIED DRUG; VACCINE;

ANTIBODY RESPONSE; ARTICLE; BIOTECHNOLOGY; COMPARATIVE STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG INDUSTRY; DRUG MARKETING; DRUG SAFETY; ECONOMIC ASPECT; EPIDEMIOLOGICAL DATA; GENITAL SYSTEM DISEASE; HEALTH CARE ORGANIZATION; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNITY; MORBIDITY; MORTALITY; NONHUMAN; PELVIC INFLAMMATORY DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROBABILITY; PROCESS DEVELOPMENT; PRODUCT DEVELOPMENT; PUBLIC-PRIVATE PARTNERSHIP; SEXUALLY TRANSMITTED DISEASE; THERAPY EFFECT; UNCERTAINTY; VACCINATION; VACCINE FAILURE; VIRUS SHEDDING;

CORRELATE OF PROTECTION; STI BURDEN; STI VACCINE DEVELOPMENT; VACCINE COMPANIES;

BIOMEDICAL RESEARCH; BIOTECHNOLOGY; DRUG INDUSTRY; HUMANS; PUBLIC-PRIVATE SECTOR PARTNERSHIPS; SEXUALLY TRANSMITTED DISEASES; VACCINES;

EID: 84896717749     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.08.032     Document Type: Article

References (61)

1. Gottlieb S., Low N., Newman L.M., Bolan G., Kamb M., Broutet N. Toward global prevention of sexually transmitted infections (STIs): the need for STI vaccines. Vaccine 2014, 32:1527-1535.
2. Douglas R.G., Samant V.B. The vaccine industry. Vaccines 2012, 157-178. Elsevier, Saunders. 6th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
3. Prifti C The vaccine industry - an overview 2013, http://www.vaccineethics.org/issue_briefs/industry.php [accessed 28.04.13].
4. College of Physicians of Philadelphia The history of vaccines 2013, http://www.historyofvaccines.org/content/articles/vaccine-development-testing-and-regulation [accessed 28.04.13].
5. European Vaccine Initiative (EVI). Stages of vaccine development, <>. http://www.euvaccine.eu/vaccines-diseases/vaccines/stages-development.
6. Sanofi Pasteur. The vaccine development cycle. (accessed 28.04.2013). http://www.sanofipasteur.com/%3FcodeRubrique=31.
7. PhRMA Vaccine fact book 2012, http://www.phrma-jp.org/archives/pdf/vaccine_factbook_2012/en/vaccine_factbook_2012_en.pdf [accessed 28.04.13].
8. GSK - Annual report 2012, http://www.gsk.com/investors/annual-reports/annual-report.html [accessed 28.04.13].
9. Levine R., Kremer M., Albright A. Making Markets for Vaccines? Ideas to action. The report of the Center for Global Development Advance Market Commitment Working Group 2005, Center for Global Development, http://www.cgdev.org/doc/books/vaccine/MakingMarkets-complete.pdf [accessed 28.04.13].
10. USAID Report to Congress - Coordinated Strategy to Accelerate Development of Vaccines for Infectious Diseases 2009, http://pdf.usaid.gov/pdf_docs/PDACN525.pdf [accessed 28.04.13].
11. Plotkin S. How companies choose projects, <> [accessed 28.04.13]. http://www.iom.edu/~/media/Files/Activity%20Files/PublicHealth/NatVaxPlan/IOM2008PrioritiesPanel3_pptReadOnly.pdf.
12. Serdobova I., Kieny M.P. Assembling a global vaccine development pipeline for infectious diseases in the developing world. Am. J. Public Health 2006, 96(9):1554-1559.
13. Salinsky E., Warble C. The vaccine industry: does it need a shot in the arm? National Health Policy Forum 2006, http://www.nhpf.org/library/background-papers/BP_VaccineIndustry_01-25-06.pdf [25.01.06: 14].
14. NIH/NIAID Vaccine research 2013, http://www.niaid.nih.gov/topics/vaccines/Pages/Default.aspx [accessed 28.04.13].
15. NIH/NIAID Vaccine Research Center (VRC) 2013, http://www.niaid.nih.gov/about/organization/vrc/pages/default.aspx/Pages/default.aspx [accessed 28.04.13].
16. NIH/NIAID About NIAID 2013, http://www.niaid.nih.gov/about/Pages/default.aspx [accessed 28.04.13].
17. USAID Immunization basics 2013, http://www.immunizationbasics.jsi.com/ [accessed 28.04.13].
18. European Vaccine Initiative (EVI).2013 [accessed 28.04.13]. http://www.euvaccine.eu/.
19. Transvac.2013 [accessed 28.04.13]. http://www.transvac.org/about-transvac.
20. Aditec Advanced immunization technologies 2013, http://www.aditecproject.eu/ [accessed 28.04.13].
21. GAVI Alliance.2013 [accessed 28.04.13]. http://www.gavialliance.org/about/mission/.
22. Bill & Melinda Gates Foundation.2013 [accessed 28.04.13]. http://www.gatesfoundation.org/.
23. IFFIm.2013 [accessed 28.04.13]. http://www.iffim.org/.
24. WHO Advanced market commitments for vaccines 2013, http://www.who.int/immunization/newsroom/amcs/en/ [accessed 28.04.13].
25. Stanberry L.R., Belshe R.B. Herpes simplex virus vaccines. Vaccines 2012, 3554-3572. Elsevier, Saunders. 6th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
26. Belshe R.B., et al. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med 2012, 366(1):26-35.
27. Schauttet K., De Clercq E., Vanrompay D. Chlamydia trachomatis vaccine research through the years. Infect Dis Obstet Gynecol 2011, (June):963513. (Epub ahead of print, 26.06.2011). 10.1155/2011/963513.
28. Plotkin S.A., Plotkin S.L. The development of vaccines: how the past led to the future. Nat Rev Microbiol 2011, 9(12):889-893.
29. Johnston C., Koelle D.M., Wald A. Current status and prospects for development of an HSV vaccine. Vaccine 2013.
30. Timms P., Hafner L.M., Wilson D. Development status and future vaccines from Chlamydia trachomatis infections. Vaccine 2014, 32:1563-1571.
31. Jerse A., Bash M.C., Russell M.W. Vaccines against gonorrhea: current status and future challenges. Vaccine 2013.
32. Smith J., Garber G. Current status and prospects for development of a vaccine against Trichomonas infections. Vaccine 2013.
33. Wang S.P., Grayston J.T., Alexander E.R. Trachoma vaccine studies in monkeys. Am J Ophthalmol 1967, 63(5 (Suppl)):1615-1630.
34. Woolridge R.L., Grayston J.T., Chang I.H., Cheng K.H., Yhang C.Y., Neave C. Field trial of a monovalent and of a bivalent mineral oil adjuvant trachoma vaccine in Taiwan school children. Am J Ophthalmol 1967, 63(5 (Suppl)):1645-1650.
35. Yim K.C., Carroll C.J., Tuyama A., Cheshenko N., Carlucci M.J., Porter D.D., et al. The cotton rat provides a novel model to study genital herpes infection and to evaluate preventive strategies. J Virol 2005, 79(23):14632-14639.
36. De Clercq E., Kalmar I., Vanrompay D. animal models for studying Chlamydia trachomatis female genital tract infection. Infect Immun 2013, [Epub ahead of print, July 8].
37. Garnett G.P. Role of heard immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis 2005, 191(Suppl. 1):S97-S106.
38. Garnett G.P. The theoretical impact and cost-effectiveness of vaccines that protect against sexually transmitted infections and disease. Vaccine 2014, 32:1536-1542.
39. Moodley P., Wilkinson D., Connolly C., Moodley J., Sturm A.W. Trichomonas vaginalis is associated with pelvic inflammatory disease in women infected with human immunideficiency virus. Clin Infect Dis 2002, 34:519-522.
40. Taylor B.D., Darville T., Haggerty C.L. Does bacterial vaginosis cause pelvic inflammatory disease?. Sex Transm Dis 2013, 40:117-122.
41. Gray R.T., Beagley K.W., Timms P., Wilson D.P. Modeling the impact of potential vaccines on epidemics of sexually transmitted Chlamydia trachomatis infection. J Infect Dis 2009, 199:1680-1688.
42. Smith R.J., Blower S.M. Could disease-modifying HIV vaccines cause population-level perversity?. Lancet Infect Dis 2004, 4:636-639.
43. WHO Global incidence and prevalence of selected curable sexually transmitted infections - 2008 2012, World Health Organization, Geneva, http://www.who.int/reproductivehealth/publications/rtis/stisestimates/en/index.html.
44. De Schryver A., Meheus A. Epidemiology of sexually transmitted diseases: the global picture. Bull WHO 1990, 68(5):639-654.
45. Cameron C.E. Current status of syphilis vaccine development: need, challenges, and prospects. Vaccine 2014, 32:1602-1609.
46. Johnston C., Saracino M., Kuntz S., Margaret A., Selke S., Huang M., et al. Ineffectiveness of daily standard and high-dose antiviral therapy in preventing short episodes of genital HSV-2 reactivation: three randomized, open-label cross-over trials. Lancet 2012, 379(9816):641-647.
47. Bernstein A., Pulendran B., Rappuoli R. Systems vaccinomics: the road ahead for vaccinology. OMICS 2011, 15(9):529-531.
48. Bagnoli F., Baudner B., Mishra R.P., Bartolini E., Fiaschi L., Mariotti P., et al. Designing the next generation of vaccines for global public health. OMICS 2011, 15(9):545-566.
49. Brunham R.C., Rappuoli R. Chlamydia trachomatis control requires a vaccine. Vaccine 2013, 31(15):1892-1897.
50. Geisler W.M., Lensing S.Y., Press C.G., Hook E.W. Spontaneous resolution of genital chlamydia trachomatis infection in women and protection from reinfection. J Infect Dis 2013, [Epub ahead of print, March 26].
51. Brotman R.M., Ravel J., Bavoil P.M., Gravitt P.E., Ghanam K.G. Microbomes, sex hormones, and immune responses in the reproductive tract: challenges for vaccine development against sexually transmitted infections. Vaccine 2013.
52. Miller F.G., Grady C. The ethical challenge of infection-inducing challenge experiments. Clin Infect Dis 2001, 33:1028-1033.
53. Pollard A.J., Savulescu J., Oxford J., Hill A.V., Levine M.M., Lewis D.J., et al. Human microbial challenge: the ultimate animal model. Lancet Infect Dis 2012, 12(12):903-905.
54. Hobbs M.M., Sparling P.F., Cohen M.S., Shafer W.M., Deal C.D., Jerse A.E. Experimental gonococcal infection in male volunteers: cumulative experience with Neisseria gonorrhoeae strains FA1090 and MS11mkC. Front Microbiol 2011, 2:123.
55. Rouse B.T., Kaistha S.D. A tale of two α-herpesviruses: lessons for vaccinologists. Clin Infect Dis 2006, 42(6):810-817.
56. IAVI International AIDS Vaccine Alliance 2013, www.iavi.org/ [accessed 28.04.13].
57. Global HIV Vaccine Enterprise. http://www.vaccineenterprise.org/.
58. HIV Vaccine Trials Network.2013 [accessed 28.04.13]. http://www.hvtn.org/.
59. OTT/NIH. CRADAS & MTAs:. [accessed 28.04.2013]. http://www.ott.nih.gov/cradas/model_agree.aspx.
60. Innovative Medicines Initiative (IMI).2013 [accessed 28.04.13]. http://www.imi.europa.eu/.
61. NIH/NIAID Sexually transmitted diseases (STDs) 2013, http://www.niaid.nih.gov/topics/std/Pages/default.aspx [accessed 28.04.13].